Bayer Aktiengesellschaft (BAYRY)

Market Cap	40.31B +45.2%
Revenue (ttm)	52.16B -2.9%
Net Income	-2.49B
EPS	-2.53
Shares Out	n/a
PE Ratio	n/a
Forward PE	7.97
Dividend	0.02 (0.23%)
Ex-Dividend Date	Apr 28, 2026

Volume	37,129
Open	10.21
Previous Close	10.15
Day's Range	10.14 - 10.30
52-Week Range	7.19 - 14.85
Beta	0.84
Analysts	Buy
Price Target	14.20 (+39.49%)
Earnings Date	May 12, 2026

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and ge...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1863
• Employees: 87,757
• Stock Exchange: OTCMKTS
• Ticker Symbol: BAYRY

Financial Performance

In 2025, Bayer Aktiengesellschaft's revenue was 45.58 billion, a decrease of -2.21% compared to the previous year's 46.61 billion. Losses were -3.62 billion, 41.8% more than in 2024.

Financial numbers in EUR

Analyst Summary

According to 4 analysts, the average rating for BAYRY stock is "Buy." The 12-month stock price target is $14.2, which is an increase of 39.49% from the latest price.

Price Target

$14.2

(39.49% upside)

Analyst Consensus: Buy